Jacob Borrajo
Vorstandsvorsitzender bei Amber Bio, Inc.
Profil
Jacob Borrajo is the founder of Coral Genomics, Inc. Mr. Borrajo is also the founder of Amber Bio, Inc.
Aktive Positionen von Jacob Borrajo
Unternehmen | Position | Beginn |
---|---|---|
Amber Bio, Inc.
Amber Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Amber Bio, Inc. is a biotechnology company based in an undisclosed location. The American company is focused on developing a first-of-its-kind RNA editing platform that can correct genetic mutations in a safe and reversible way. Amber Bio is pioneering new gene editing modalities using multi-kilobase RNA writing to reach previously undruggable diseases. Co-founders Jacob Borrajo and Basem Al-Shayeb received their Ph.D. at leading institutions for gene editing research: Broad Institute of MIT & Harvard and University of California. Jacob Borrajo has been the CEO since incorporation. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Jacob Borrajo
Unternehmen | Position | Ende |
---|---|---|
Coral Genomics, Inc.
Coral Genomics, Inc. Pharmaceuticals: MajorHealth Technology Coral Genomics, Inc. operates as a biotechnology company that optimizes drug development and deployment by utilizing genomic data from patients. The company was founded by Jacob Borrajo and Atray Dixit in 2018 and is headquartered in San Francisco, CA. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Coral Genomics, Inc.
Coral Genomics, Inc. Pharmaceuticals: MajorHealth Technology Coral Genomics, Inc. operates as a biotechnology company that optimizes drug development and deployment by utilizing genomic data from patients. The company was founded by Jacob Borrajo and Atray Dixit in 2018 and is headquartered in San Francisco, CA. | Health Technology |
Amber Bio, Inc.
Amber Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Amber Bio, Inc. is a biotechnology company based in an undisclosed location. The American company is focused on developing a first-of-its-kind RNA editing platform that can correct genetic mutations in a safe and reversible way. Amber Bio is pioneering new gene editing modalities using multi-kilobase RNA writing to reach previously undruggable diseases. Co-founders Jacob Borrajo and Basem Al-Shayeb received their Ph.D. at leading institutions for gene editing research: Broad Institute of MIT & Harvard and University of California. Jacob Borrajo has been the CEO since incorporation. | Commercial Services |